Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580870 | 0.75 | POLB (0.44) | CNR2POLBCNR1LMNANPSR1 | |
| SCHEMBL28045859 | 0.74 | POLB (0.41) | CNR2POLBCNR1LMNANPSR1 | |
| SCHEMBL1924214 | 0.72 | SMN1; SMN2 (0.48) | MAPK1NPSR1MEN1MAPTKMT2A | |
| SCHEMBL20604979 | 0.72 | NR4A2 (0.59) | CYP1A2CYP2C19MEN1MAPTKMT2A | |
| SCHEMBL7501630 | 0.72 | KMT2A (0.40) | CNR2POLBCNR1LMNANPSR1 | |
| SCHEMBL7469126 | 0.71 | ABCG2 (0.52) | MAPK1HPGDCYP1A2CYP2C19MEN1 | |
| SCHEMBL7928540 | 0.68 | CYP1A2 (0.52) | POLBMAPK1HPGDLMNACYP1A2 | |
| SCHEMBL941698 | 0.67 | CES2 (0.74) | MAPK1HPGDCYP3A4ALOX15MEN1 | |
| SCHEMBL30250451 | 0.67 | CES2 (0.74) | MAPK1HPGDCYP3A4ALOX15MEN1 | |
| SCHEMBL29613672 | 0.67 | CES2 (0.74) | MAPK1HPGDCYP3A4ALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812426-B1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2011-06-08 | — | — | EP | disclosed |
| US-20090075985-A1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS INC. (US) | 2009-03-19 | — | — | US | disclosed |
| EP-1812426-A1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060142348-A1 | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease | DECODE CHEMISTRY, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| WO-2006044405-A1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142348-A1 | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, TBXA2R | CNR2 280/4885POLB 465/4885CNR1 594/4885 |
| US-20090075985-A1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | PTGIS, PTGIR, TBXA2R | CNR2 280/4885POLB 465/4885CNR1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.